Salvage stereotactic body radiotherapy for post-operative oligo-recurrence of non-small cell lung cancer: A single-institution analysis of 59 patients.
Salvage stereotactic body radiotherapy for post-operative oligo-recurrence of non-small cell lung cancer: A single-institution analysis of 59 patients. Oncol Lett. 2020 Apr;19(4):2695-2704 Authors: Aoki S, Yamashita H, Takahashi W, Nawa K, Ota T, Imae T, Ozaki S, Nozawa Y, Nakajima J, Sato M, Anraku M, Nitadori J, Karasaki T, Abe O, Nakagawa K Abstract A standard treatment for patients with early-stage non-small cell lung cancer (NSCLC) who undergo surgery, and subsequently develop local failure or intrathoracic oligo-recurrence, has not yet been established. The present study aimed to assess the feasibility of stereotactic body radiotherapy (SBRT) for this subgroup of patients. Consequently, a retrospective analysis was conducted of patients with NSCLC recurrence who were treated with SBRT, and previously underwent curative surgical resection between October 2011 and October 2016. Post-SBRT survival [overall survival (OS); progression-free survival (PFS); and local control (LC)] and toxicity were analyzed. Prognostic factors for OS were identified using univariate and multivariate analysis. A total of 52 patients and 59 tumors were analyzed. The median follow-up time was 25 months (35 months for surviving patients), and median OS following salvage SBRT was 32 months. The 1- and 3-year OS rates were 84.4 and 67.8%, respectively. 1- and 3-year PFS rates were 80.8 and 58.7%, respectively. Only 4 patients (7.7%) developed local failure. Median LC was 71 mont...
Conclusions: In this cohort, only 35.1% of patients eligible for post-PD1 Ab therapy received st. Post-progression survival was not significantly affected by receipt of post-progression therapy. Prospective trials are needed to clarify the benefit of post-PD1 Ab treatments. PMID: 32489249 [PubMed - in process]
Conclusions: The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study. Improving access to supportive care through the collection of patient-reported outcomes and hrqol should be an important component of care for patients with advanced lung cancer. PMID: 32489264 [PubMed - in process]
Conclusions: This Canadian expert consensus statement and algorithm were driven by significant advances in the treatment of EGFR-mutated nsclc. PMID: 32489263 [PubMed - in process]
Condition: Unresectable Non-small Cell Lung Cancer (NSCLC) and Urothelial Cancer Intervention: Drug: Durvalumab Sponsor: AstraZeneca Not yet recruiting
(Wake Forest Baptist Medical Center) Among people who have the most common type of lung cancer, up to 40% develop metastatic brain tumors, with an average survival time of less than six months. But why non-small-cell lung cancer so often spreads to the brain has been poorly understood.
Publication date: Available online 2 June 2020Source: PhytomedicineAuthor(s): Huan Wu, Lina Wang, Xiang Zhan, Bin Wang, Jiawen Wu, An Zhou
Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study. Med Sci Monit. 2020 Jun 02;26:e922675 Authors: Zhai X, Guo Y, Qian X Abstract BACKGROUND The early diagnosis of lymph node (LN) metastasis is crucial for patients with non-small cell lung cancer (NSCLC). However, the diagnosis of LN metastasis mainly dependent on ¹⁸F-FDG PET/CT (fluorine-18 fluorodeoxyglucose positron-emission tomography/computed tomo...
CONCLUSIONS Medium-immune scores are correlated with unsatisfactory prognosis in NSCLC (stage I-II) patients. In addition, the prognostic nomogram may be helpful in predicting OS for stage I and II NSCLC patients. PMID: 32479428 [PubMed - in process]
(University of Missouri-Columbia) Non-small cell lung cancer (NSCLC) is the most common type of lung cancer where tumor cells shed from the main tumor circulate in the blood and settle in other organs and metastasize. In some cases, surgery can remove the primary tumor, but investigators from the University of Missouri School of Medicine have identified a type of cell fusion between cancer cells and white blood cells called a tumor-macrophage fusion (TMF) where the size and number of the TMF cells may predict survival.
Lung cancer has high morbidity and mortality worldwide with non-small cell lung cancer (NSCLC) accounting for 85% of the cases. Therapies for lung cancer have relatively poor outcomes and further improvements ...